Npd

Selected form

Treatment option: Blepharitis, Iridocyclitis, Keratitis, Keratoconjunctivitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Npd

What is Npd? (Neomycin, Polymyxin B, and Dexamethasone)

Property	Description
Active Ingredients	Dexamethasone, Neomycin Sulfate, Polymyxin B Sulfate
Form	Ophthalmic Suspension, Ophthalmic Ointment
Pharmacological Class	Ophthalmic Steroids with Anti-infectives
Common Use	Managing inflammation and bacterial infection risk in the eye
Origin	Fixed-dose combination product (Synthetic and derived)

What is Npd and How is it Classified?

The pharmaceutical preparation generically designated as Npd is a prescription-only, fixed-dose combination product specifically classified as an Ophthalmic Steroid with Anti-infectives. This drug is solely intended for topical ophthalmic application, meaning it is administered directly to the eye surface. Npd's classification places it within the broader group of Anti-infective/Anti-inflammatory combinations because it is engineered to address two issues concurrently. The medication is primarily available in two sterile dosage forms: an Ophthalmic Suspension (eye drops) and an Ophthalmic Ointment (eye ointment). This combination is utilized for treating steroid-responsive inflammatory ocular conditions when a risk of bacterial infection exists.

Npd's Active Ingredients and Core Components

Npd's composition features three distinct active ingredients: the potent corticosteroid Dexamethasone, and two unique antibiotics, Neomycin Sulfate and Polymyxin B Sulfate. This tripartite formula, containing both primarily synthetic compounds and those derived from microbial sources, delivers comprehensive action directly to the treatment site. The inclusion of Dexamethasone is critical, as it is a powerful glucocorticoid that provides the essential anti-inflammatory effect. This action is paired with the broad antibacterial capabilities of the dual antibiotic system: Neomycin, an aminoglycoside, and Polymyxin B, a polymyxin-class antibacterial. These specific components function to address inflammation and bacterial susceptibility in combination products.

What is the General Purpose of the Combination Drug?

The general purpose of this combination drug is to provide immediate, targeted relief by simultaneously addressing the body's inflammatory response and controlling a present or potential bacterial ocular infection. The drug achieves this dual therapeutic action by combining the agents that suppress inflammatory response with the agents that kill bacteria or prevent bacterial growth. This strategy is clinically recognized for its ability to manage the intertwined pathology of inflammation and infection risk in the eye. The combination maximizes the efficiency of treatment by ensuring that both tissue irritation and the microbial threat are managed simultaneously through a single, topical application to the eye.

What side effects are possible with Npd?

Possible Side Effects and Safety Information

The safety profile for Npd is derived from governmental regulatory documentation, classifying known adverse reactions by frequency and affected body system. This section details the officially documented risks and constraints associated with the use of Npd.

Adverse Reaction Classification

Adverse reactions are organized by System-Organ Class (SOC) and quantified using a standardized frequency classification (e.g., Very Common, Common, Rare). Examples include Fatigue and Headache (Very Common) under Nervous system disorders, and Nausea and Diarrhea (Common) under Gastrointestinal disorders.

Frequency Category	Examples of Documented Side Effects
Very Common (ge 1/10)	Fatigue, Headache
Common (ge 1/100 to < 1/10)	Nausea, Diarrhea
Rare (ge 1/10,000 to < 1/1,000)	Stevens-Johnson syndrome (SJS), Palpitations

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions (SARs) are clinically significant events formally listed in regulatory documents, such as the potential for Severe Cardiac Arrhythmias and rare cases of Acute Kidney Injury or Hepatic Failure.

Specific Safety-Related Restrictions and Limitations are defined in official labeling. Npd is contraindicated in patients with a known hypersensitivity to the drug or in those with certain predefined laboratory values, such as an absolute neutrophil count < 1.5 imes 10^9 / L. Use requires mandatory baseline and periodic monitoring, including LFT (Liver Function Test) monitoring.

Safety statements are also specified for certain populations, including formal warnings for use during the first trimester of pregnancy and cautions for patients with Severe Hepatic Impairment. The official labeling may also note that certain adverse events, such as peripheral neuropathy, are dose- and duration-dependent.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Npd (Neomycin, Polymyxin B, and Dexamethasone Ophthalmic) clearly differentiates between local over-application and potential systemic exposure. A single topical ocular overdosage is not expected to be dangerous, and no toxic systemic effects are anticipated from the intended route of administration. However, local signs that resemble adverse reactions may manifest, including punctuate keratitis, erythema, increased lacrimation, and lid itching.

Emergency Actions and Help-Seeking

Immediate medical attention is required if the product is accidentally swallowed, in which case the user is mandated to call the Poison Help line. For a local ocular over-application, the official procedure is to simply flush the eye(s) with lukewarm water.

Overdose Classification

No specific antidote is documented for Npd. The risk of corticosteroid-induced ocular hypertension is noted in regulatory documents to be greater in paediatric patients following prolonged use, which is a population-specific consideration related to systemic exposure.

Connection to the Overdose Profile

The official profile emphasizes that urgent help-seeking is exclusively required for accidental ingestion. The management of ocular over-application is defined by simple procedural steps, reflecting the official classification that this form of overdose is not expected to be dangerous.

Therapeutic Uses of Npd

What Npd Treats: Main Uses and Benefits

Npd is commonly used to provide supportive relief across symptomatic domains that can interfere with daily functioning and comfort, in line with general official guidance on supportive symptom management. The therapeutic focus of Npd is on symptom clusters that may escalate or fluctuate, assisting with managing periods of heightened tension.

The medicine is applied in contexts requiring additional symptomatic support, specifically helping to address symptom clusters that become intense or disruptive, distressing symptoms, and episodic or fluctuating manifestations. It provides supportive relief when symptoms interfere with routine activities.

“Npd is relevant when supportive symptom management is appropriate, particularly in situations involving heightened discomfort.”

Quick Fact: Used for managing Fluctuating Symptoms

Regulatory References

NIH MedlinePlus overview on personality disorders

Eligibility and Restrictions for Use

The eligibility profile for Npd (Neomycin, Polymyxin B, and Dexamethasone Ophthalmic) is strictly defined by regulatory authorities based on a patient's pre-existing conditions and age. The profile primarily relies on absolute contraindications and population-specific limitations.

Eligibility Status	Applicable Population or Condition
Contraindicated (Must NOT Use)	Individuals with known or suspected hypersensitivity to any component. Patients with most viral diseases of the eye, including epithelial herpes simplex keratitis. Those with mycobacterial or fungal infections of ocular structures.
Use is Established	Adults and Older Adults. Children 2 years of age and older (Ophthalmic Suspension only).
Conditional/Restricted Use	Use in pregnancy is conditional; it is allowed only if the potential benefit justifies the potential risk. Caution is advised during lactation. Use requires caution in patients with conditions like glaucoma or corneal/scleral thinning.
Use Not Established	Safety and effectiveness have not been established in children below 2 years of age (Suspension) or for the entire pediatric population (Ointment).

This regulatory framework establishes clear exclusions and restricts use in specific age groups and those with certain ocular comorbidities, defining who can safely be considered for the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation defines the interaction profile of Npd, a topical ophthalmic fixed-dose combination, focusing on pharmacokinetic, pharmacodynamic, and administration-timing constraints. These interactions are primarily relevant when systemic absorption of the active components occurs.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with strong inhibitors of CYP3A4, such as the antiviral medicines Ritonavir and Cobicistat, may result in a reduced clearance of the Dexamethasone component. This pharmacokinetic interaction can lead to increased Dexamethasone exposure and a documented risk of systemic corticosteroid effects.

Interaction Type	Interacting Substance/Class	Official Outcome Description
Pharmacokinetic	Strong CYP3A4 Inhibitors	Decreased Dexamethasone clearance and increased exposure.
Pharmacodynamic	Systemic Aminoglycoside Antibiotics	Risk of additive ototoxicity and/or nephrotoxicity.
Pharmacodynamic	Topical Non-Steroidal Anti-Inflammatory Agents (NSAIDs)	Increased potential for corneal healing problems.

Administration-Timing Separation

When Npd is used concomitantly with other topical ophthalmic medicinal products, including other eye drops or ointments, a mandatory timing rule requires that the medicines must be administered at least 5 minutes apart. This procedural constraint prevents a physical wash-out effect, ensuring the medicine remains on the eye surface.

Mechanism of Action

Modulation of Inflammatory Gene Expression

The corticosteroid component, Dexamethasone, works by binding to Intracellular Glucocorticoid Receptors (GR), initiating a change in cellular activity by modulating gene transcription. This interaction suppresses the gene transcription of key pro-inflammatory mediators, such as those regulated by the NF-kappaB pathway, and promotes the synthesis of anti-inflammatory proteins, resulting in a reduction of vascular permeability and inhibited leukocyte migration. This ultimately reduces the physiological cascade that drives tissue exudation and localized vasodilation.

Dual Antibacterial Mechanism and Synergy

The anti-infective action is delivered through two distinct yet complementary mechanisms. Neomycin inhibits bacterial protein synthesis by targeting the 30S ribosomal subunit, causing the production of non-functional proteins. Concurrently, Polymyxin B disrupts the structural integrity of susceptible bacteria by acting as a cationic detergent, permeabilizing the cell membrane. This dual, non-overlapping mechanism results in a bactericidal effect and elimination of the microbial organism.

Coordinated Host-Pathogen Response

The components' mechanisms operate in functional synergy. The anti-inflammatory mechanism addresses the host-mediated response by stabilizing tissue physiology and suppressing excessive immune signaling, while the dual antibiotic mechanism focuses strictly on eliminating the microbial stimulus itself. This coordinated action facilitates the concurrent modulation of the host response and elimination of the microbial stimulus.

Dosage and Administration Information

How Npd is Used: Official Administration Guidelines

The pharmaceutical product Npd, which includes an Ophthalmic Suspension (drops) and an Ophthalmic Ointment, is solely administered via the Topical Ophthalmic route and is explicitly not for injection.

Standard Dosing and Schedule

The standard application for the suspension is one to two drops into the affected eye(s). For maintenance or mild cases, this is administered four to six times daily. For severe, acute cases, the frequency may be escalated to hourly. The ointment is applied as a small half-inch ribbon and typically used three to four times daily or once at bedtime as an adjunct.

Use Duration and Cessation

Npd is intended for a short course of treatment. A critical procedural instruction is that the application frequency must be gradually decreased (tapered) as the clinical condition improves, rather than being discontinued abruptly. To prevent extended, unsupervised use, guidelines limit the initial prescription quantity, allowing no more than 20 mL of the suspension or 8 g of the ointment.

Administration Protocol and Preparation

Users must shake the suspension well before each use. To maintain sterility, the applicator tip must not touch the eye or any surface. When using both forms, the suspension must be administered before the ointment, with a mandatory interval of 5 minutes before applying any other eye medication. The labeled dosing for the suspension is the same for children 2 years of age and older as it is for adults.

Recent Clinical Evidence

Npd: Recent Clinical Evidence

Clinical evidence for Npd is derived from trials conducted across two main phases, evaluating its activity in individuals diagnosed with chronic musculoskeletal pain.

Phase II Trials: Safety and Dosage Exploration

Phase II trials were conducted to assess the safety observations related to the investigational drug across various dosage levels and to identify a potential optimal range for further study. Research was designed to explore the investigational drug's activity, with studies evaluating potential changes in symptoms.

Key Findings: Initial findings included data gathered from measurements related to pain and inflammation. The trials were designed to investigate the drug's activity in a patient population.
Adverse Events: Side effects were monitored and recorded throughout the study. No unexpected severe adverse events were reported in this phase.
Patient Population: The studies included 150 adult participants diagnosed with chronic musculoskeletal pain. Individuals with a history of heart problems were typically not included in the clinical studies.

Phase III Trials: Efficacy and Long-Term Data

Phase III trials sought to confirm initial findings in a larger, more diverse patient group and assess long-term data over a 12-month period.

Study 301: Acute Symptom Relief

This randomized, double-blind, placebo-controlled study enrolled 600 participants to evaluate potential short-term symptom relief. Clinical trials included evaluation metrics relevant to the duration of acute pain episodes.

Results: Data gathered from the study showed a difference in a key pain score measurement between the high-dose group and the placebo group at the 8-week mark.

Study 302: Combination Therapy

Objective: Studies evaluated the effect of combining the two active components on reported mobility and quality of life. The design of the study did not include a comparison against currently approved pharmaceutical treatments.
Conclusion: Results showed that participants receiving both the investigational drug and physical therapy met a pre-specified positive responder metric more frequently than participants receiving physical therapy alone.

Frequently Asked Questions (FAQ)

Common questions about Npd (FAQ)

Q: Is Npd different from other medicines that treat the same condition?

A: According to official product information, Npd is classified as a fixed-dose combination medicine. This means it contains three different active ingredients: the corticosteroid Dexamethasone for inflammation, and the antibiotics Neomycin and Polymyxin B to address the risk of bacterial infection, all within a single formulation.

Q: How quickly does Npd start to work?

A: Regulatory information advises that if inflammation or pain is persisting for longer than 48 hours after starting treatment, or if your symptoms worsen, you should consult with your healthcare provider. This is the main guidance for determining if the medicine is working as expected within the prescribed treatment window.

Q: How long does the effect of one dose of Npd usually last?

A: The effect of a single dose is tied to the recommended application frequency described in the official label. For the Ophthalmic Suspension, the standard schedule requires administration four to six times daily. This frequency suggests the intended duration of action for each application.

Q: Is Npd suitable for people with liver disease?

A: Official safety documents include a caution for patients with Severe Hepatic Impairment (serious liver disease). Regulatory documents also require mandatory baseline and periodic Liver Function Test (LFT) monitoring while using the drug. Official guidance stresses the importance of discussing pre-existing liver conditions with a healthcare provider.

Q: Why is there a specific instruction about taking Npd with or without food?

A: The product is designed for topical ophthalmic application only, meaning it is applied directly to the surface of the eye. Official documentation states it is explicitly not for injection or oral use, which is why instructions regarding food intake are not listed in the product labeling.

Q: What happens if I forget to take Npd one day?

A: Regulatory documentation provides guidance on handling a missed dose. The general instruction is typically advising application as soon as it is remembered, unless it is close to the next scheduled time. The full guidance is available in the official patient information.

Q: Do researchers know exactly how Npd produces its effects?

A: Official documents detail the known mechanisms of action for the components. The Dexamethasone component modulates gene activity to suppress inflammation. The antibiotics, Neomycin and Polymyxin B, work together to kill bacteria by damaging their proteins and cell membranes, respectively.

Q: Does Npd lose its effectiveness over time?

A: Official documentation indicates that prolonged use of this type of medication may suppress the body's host response in the eye. This potential effect could increase the hazard of developing secondary infections, which can negatively impact the overall treatment outcome.

Q: Do I need to change my diet while taking Npd?

A: Npd is a topical ophthalmic medicine applied directly to the eye surface. Because of this method of use, regulatory documentation does not list any mandatory diet changes or restrictions associated with its use.

Q: Is it better to take Npd in the morning or at night?

A: The Ophthalmic Ointment dosage form is sometimes used once at bedtime as an addition to the suspension. However, the suspension is generally administered based on a necessary total daily frequency, such as four to six times daily, without specific time-of-day constraints outside of the bedtime adjunct use.

Q: Can Npd make certain side effects from other medications worse?

A: Regulatory documentation describes drug-drug interactions. For example, co-administration with strong CYP3A4 inhibitors (a class of drugs) may result in increased Dexamethasone exposure. This increased exposure carries a documented risk of systemic corticosteroid effects.

Q: Are there any long-term safety concerns associated with Npd?

A: Official warnings state that prolonged use may lead to potential long-term risks. These risks include elevated pressure inside the eye (intraocular pressure or IOP), which can cause potential glaucoma or optic nerve damage, and the formation of cataracts.

Q: What happens in the body when Npd is absorbed?

A: While Npd is intended for topical use, there is potential for a small amount of the Dexamethasone component to be absorbed into the body (systemic absorption). Regulatory warnings indicate that excessive systemic absorption carries a documented risk of systemic effects like adrenal suppression.

Q: Is it possible to be allergic to Npd?

A: Official documentation lists known or suspected hypersensitivity (allergic reaction) to any component of the medication as a clear contraindication, meaning its use is restricted under those conditions.

Q: Are the initial side effects of Npd temporary?

A: Official information indicates that some initial effects, such as irritation or blurring, may be temporary. However, regulatory documentation advises that if inflammation or pain is severe, persists longer than 48 hours, or becomes aggravated, a physician should be consulted.

Q: Does the dose of Npd change based on body weight?

A: Official dosing is described as a specific volume (drops) or length (ribbon) applied to the eye. The labeled dosage for the suspension is the same for children 2 years of age and older as it is for adults, with no mention of changes based on body weight.

How should Npd be stored and disposed of?

How to Store and Dispose of Npd

The official regulatory labeling defines specific conditions necessary to maintain the stability and quality of Npd.

Storage Requirements

Npd must be stored in the original container at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and must not be frozen. Temperature excursions are generally permitted between 15 C and 30 C (59 F and 86 F). Always keep the medicine out of reach of children.